Novartis hit after data probe
Novartis shares have fallen after US regulators said a unit that developed a costly breakthrough gene therapy knew about potential manipulation of animal testing data but failed to disclose it before the treatment was approved.
The Business Hub
Newsletter
News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.





